Search clinical trials for: multiple site study

Total 179287 results

Caribou Biosciences, Inc.

Enrolling by invitation

Long-Term Follow-up Study (LTFS)

Lymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Hematologic Malignancy | Relapsed/Refractory Multiple Myeloma | Relapsed/Refractory Acute Myeloid Leukemia | Relapsed Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin's Lymphoma

United States
Hoffmann-La Roche

Completed

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)

Melanoma

United States, Italy, Australia, France, Spain, Netherlands
Hoffmann-La Roche
BioLineRx, Ltd.; Halozyme Therapeutics

Active, not recruiting

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma

United States, United Kingdom, Australia, Korea, Republic of, Taiwan, Israel, Spain
Bayer

Active, not recruiting

An Observational Study to Learn More About the Impact of Gadoxetate Sodium-Enhanced Magnetic Resonance Imaging (EOB-MRI) When Used to Diagnose the Spread of Cancer From the Pancreas to the Liver in Japanese People Under Real-World Conditions

Liver Metastases | Metastatic Pancreatic Cancer | Gadoxetate Sodium-enhanced Magnetic Resonance Imaging

Japan
Pfizer

Active, not recruiting

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

Multiple Myeloma

United States, Canada, Spain, Belgium, United Kingdom, Australia, Japan, France, Germany, Poland
Sanofi

Completed

Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Multiple Myeloma

France, Spain, Belgium, Australia, United States, Japan
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...
EMD Serono Research & Development Institute, Inc.

Terminated

Study of Evobrutinib in Participants With RMS (evolutionRMS 1)

Relapsing Multiple Sclerosis

United States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Colombia, Croatia, Czechia, Estonia, Finland, France, Georgia, Germany, Hong Kong, Hungary, India, Israel, Italy, Korea, Republic of, M... and more
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...
EMD Serono Research & Development Institute, Inc.

Terminated

Study of Evobrutinib in Participants With RMS (evolutionRMS 2)

Relapsing Multiple Sclerosis

United States, Belarus, Brazil, Bulgaria, Canada, France, Germany, Greece, India, Italy, Latvia, Lithuania, Malaysia, Moldova, Republic of, Norway, Philippines, Poland, Portugal, Puerto Rico, Romania, Russian Federation, Saudi Arabia and more
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis

Relapsing-remitting Multiple Sclerosis

Spain, Czechia, Bulgaria, Serbia, Russian Federation, Ukraine, Poland, Slovakia
Novartis Pharmaceuticals

Terminated

Multiple Ascending Dose Study of MHS552 in Adults Participants With Systemic Lupus Erythematosus (SLE)

Lupus Erythematosus, Systemic

Germany
Pfizer

Active, not recruiting

Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (COLUMBUS)

Melanoma

Canada, United States, Spain, Germany, Korea, Republic of, Australia, Czechia, Netherlands, France, Hungary, United Kingdom, Switzerland, Singapore, Russian Federation, Italy, Japan, Israel, Brazil, Portugal, Mexico, Greece, Argen... and more
Bayer

Active, not recruiting

Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer (REASSURE)

Metastatic Castration-resistant Prostate Cancer

United States, Austria, Czechia, Israel, Italy, Germany, United Kingdom, France, Mexico, Belgium, Canada, Colombia, Greece, Luxembourg, Netherlands, Spain, Denmark, Sweden, Argentina, Portugal
Janssen Research & Development, LLC

Active, not recruiting

A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-1)

Hematological Malignancies

Canada, United States, France, Italy, United Kingdom, Germany, Belgium, Netherlands, Spain, Sweden, China
Janssen Pharmaceutical K.K.

Active, not recruiting

A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Hematologic Malignancies

Japan
Takeda

Completed

Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis"

Multiple Sclerosis

Japan
Eli Lilly and Company

Completed

A Study of LY3502970 in Participants With Normal and Impaired Renal Function

Healthy | Renal Insufficiency

United States
Novartis Pharmaceuticals

Active, not recruiting

An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab (ARTIOS)

Relapsing Multiple Sclerosis

United States, Poland, Austria, Belgium, Czechia, Germany, Australia, Switzerland, Lebanon, Argentina, Canada, Slovenia, Bulgaria, Latvia, Russian Federation, Spain, Italy, Turkey, Slovakia, Portugal, Greece, Saudi Arabia, Hungary, No... and more
Eli Lilly and Company
Incyte Corporation

Active, not recruiting

A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata (BRAVE-AA1)

Alopecia Areata

United States, Puerto Rico, Japan, Mexico, Korea, Republic of
Celgene

Active, not recruiting

A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma

Multiple Myeloma

United States, Australia, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Spain, United Kingdom
Eli Lilly and Company

Active, not recruiting

A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial (SUMMIT)

Obesity | Heart Failure With Preserved Ejection Fraction (HFpEF)

China, United States, Taiwan, Mexico, Brazil, Argentina, Israel, India, Puerto Rico, Russian Federation
Eli Lilly and Company

Active, not recruiting

A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction

Chronic Heart Failure With Reduced Ejection Fraction

United States, Japan
Sanofi

Active, not recruiting

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1) (GEMINI 1)

Relapsing Multiple Sclerosis

Spain, United States, Mexico, Japan, Austria, Belarus, Bulgaria, Canada, China, Czechia, Denmark, Estonia, Finland, Germany, Italy, Lithuania, Poland, Romania, Russian Federation, Sweden, Taiwan, Turkey, Ukraine, Hong Kong
Eli Lilly and Company

Active, not recruiting

A Multiple Dose Study of LY3209590 in Participants With Type 2 Diabetes

Diabetes Mellitus, Type 2

Germany
Eli Lilly and Company

Active, not recruiting

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO)

Obesity | Overweight

Spain, United States, Australia, Italy, Hungary, India, Israel, Canada, China, Taiwan, United Kingdom, Belgium, France, Germany, Mexico, Romania, Poland, Argentina, Brazil, Puerto Rico, Austria, Turkey, Japan, Netherlands, Korea, Republic... and more
Sanofi

Active, not recruiting

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2) (GEMINI 2)

Relapsing Multiple Sclerosis

United States, Argentina, Belgium, Brazil, Canada, Chile, Croatia, Czechia, France, Germany, Greece, Hungary, India, Israel, Korea, Republic of, Latvia, Netherlands, Norway, Portugal, Puerto Rico, Russian Federation, Serbia, Slovakia, Spai... and more
Eli Lilly and Company

Active, not recruiting

A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease (ATTAIN-J)

Obesity

Japan
GlaxoSmithKline

Completed

A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Multiple Myeloma

China
Eli Lilly and Company

Active, not recruiting

A Study of LY3541105 in Healthy and Overweight Participants

Healthy | Overweight

United States
Sanguine Biosciences

Completed

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

Depression | Melanoma | Epilepsy | Lymphoma | Multiple Sclerosis | Kidney Cancer | Cervical Cancer | Diabetes Mellitus | Leukemia | Breast Cancer | Chronic Kidney Diseases | Chronic Obstructive Pulmonary Disease | Parkinson's Disease | Systemic Lupus Erythematosus | Multiple Myeloma | Hepatitis B | Insomnia | Colorectal Cancer | HIV/AID... and other conditions

United States
Eli Lilly and Company

Active, not recruiting

A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-INS)

Glucose Metabolism Disorders | Diabetes Mellitus | Endocrine System Diseases | Metabolic Disease | Diabetes Type 2

China
Eli Lilly and Company

Active, not recruiting

A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Obesity | Overweight

United States
Eli Lilly and Company

Active, not recruiting

A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)

Obesity | Overweight | Type 2 Diabetes

United States, China, Australia, India, Germany, Greece, Argentina, Korea, Republic of, Brazil, Czechia, Puerto Rico
Eli Lilly and Company

Active, not recruiting

A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) (SURPASS-SWITCH)

Type 2 Diabetes

United States, Belgium, Germany, Mexico, Romania
Eli Lilly and Company

Active, not recruiting

A Study of LY3561774 in Participants With Mixed Dyslipidemia (PROLONG-ANG3)

Metabolic Diseases | Dyslipidemias | Lipid Metabolism Disorders | Hyperlipoproteinemia

United States, Mexico, Poland, Canada, Turkey, Japan, Argentina
Eli Lilly and Company

Active, not recruiting

A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1) (QWINT-1)

Type 2 Diabetes | T2D

United States, Mexico, Argentina, Puerto Rico
Eli Lilly and Company

Active, not recruiting

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (CYCLONE 3)

Urogenital Neoplasms | Prostatic Neoplasms | Neoplasm Metastasis | Enzyme Inhibitors | Antineoplastic Agents | Hormones | Physiological Effects of Drugs | Antineoplastic Agents, Hormonal | Androgens | Hormones, Hormone Substitutes, and Hormone Antagonists | Abiraterone Acetate | Steroid Synthesis Inhibitors | Cytochrome... and other conditions

China, Canada, France, United States, Australia, Czechia, Hungary, Spain, Germany, Japan, Taiwan, Netherlands, Mexico, Belgium, Korea, Republic of, Turkey, Argentina, Romania, United Kingdom, Italy, Israel, Brazil, Poland, Greece
Eli Lilly and Company

Active, not recruiting

A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes (SURPASS-EARLY)

Type 2 Diabetes

United States, United Kingdom, Germany, Mexico, Romania, Argentina, Canada, Puerto Rico, Israel, Italy, Slovakia
Eli Lilly and Company

Active, not recruiting

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)

Obesity | Overweight | Overweight or Obesity

United States, China, India, Taiwan, Japan, Brazil, Puerto Rico, Spain, Slovakia, Korea, Republic of
Eli Lilly and Company

Active, not recruiting

A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab (ADapt)

Atopic Dermatitis

United States
Bayer

Active, not recruiting

Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the Bone (RAPIT)

Castration-resistant Prostate Cancer

Taiwan
TG Therapeutics, Inc.

Active, not recruiting

An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis (RMS)

United States, Belarus, Croatia, Georgia, Poland, Russian Federation, Serbia, Ukraine
Eli Lilly and Company

Active, not recruiting

A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both (SURPASS-PEDS)

Glucose Metabolism Disorders | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases | Type2 Diabetes | Metabolic Disease | T2DM (Type 2 Diabetes Mellitus) | T2D

United States, India, Australia, United Kingdom, Mexico, Brazil, Israel, France, Italy
AstraZeneca

Active, not recruiting

Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours

Solid Tumors

United Kingdom, Canada
GlaxoSmithKline
Merck Sharp & Dohme LLC

Completed

Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 4)

Multiple Myeloma

Spain, Germany, United States, Canada
Ono Pharmaceutical Co. Ltd

Completed

Multiple-dose Study of FOY-305 in Japanese Healthy Adult Male Subjects

Healthy Volunteers

Japan
Biogen

Active, not recruiting

A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

Alzheimer's Disease

Korea, Republic of, United States, Spain, Belgium, Italy, Australia, Canada, Switzerland, Portugal, Taiwan, France, Poland, Germany, Netherlands, Sweden, Austria, Denmark, Japan, United Kingdom, Finland
Eli Lilly and Company

Completed

A Study of LY3848575 in Healthy Participants

Healthy

United States
Bayer

Active, not recruiting

A Real-World Study to Learn More About the Order of Different Treatments and Their Effects in People With Metastatic Colorectal Cancer Receiving Their Third and Fourth Line of Treatment (RegoSeq)

Metastatic Colorectal Cancer

Spain, Italy, France
89bio, Inc.
ProSciento, Inc.

Completed

A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH

NASH

United States, Puerto Rico
Eli Lilly and Company

Completed

A Study of LY3841136 in Healthy and Overweight Participants

Healthy | Obesity

United States

Search clinical trials for: multiple site study

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations